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Abstract
The transporter associated with antigen processing (TAP) is essential for peptide loading onto major histocompatibility
complex (MHC) class I molecules by translocating peptides into the endoplasmic reticulum. The MHC-encoded ABC
transporter works in concert with the proteasome and MHC class I molecules for the antigen presentation on the cell surface
for T cell recognition. TAP forms a heterodimer where each subunit consists of a hydrophilic nucleotide binding domain and
a hydrophobic transmembrane domain. The transport mechanism is a multistep process composed of an ATP-independent
peptide association step which induces a structural reorganization of the transport complex that may trigger the ATP-driven
transport of the peptide into the endoplasmic reticulum lumen. By using combinatorial peptide libraries, the substrate
selectivity and the recognition principle of TAP have been elucidated. TAP maximizes the degree of substrate diversity in
combination with high substrate affinity. This ABC transporter is also unique as it is closely associated with chaperone-like
proteins involved in bonding of the substrate onto MHC molecules. Most interestingly, virus-infected and malignant cells
have developed strategies to escape immune surveillance by affecting TAP expression or function. ß 1999 Elsevier Science
B.V. All rights reserved.
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1. Introduction ^ overview of the MHC class I antigen
processing pathway
Under normal conditions class I molecules of the
major histocompatibility complex (MHC) present
peptides derived from endogenous proteins on the
cell surface of every nucleated cell (Fig. 1). During
viral infection or malignant transformation, an addi-
tional set of peptides bound to MHC class I mole-
cules is delivered to the cell surface for presentation
to cytotoxic T lymphocytes (CTL). The recognition
of MHC class I molecules (‘self-component’) loaded
with peptides derived from ‘non-self’ proteins by
CTL via the T cell receptors eventually leads to the
lysis/apoptosis of abnormal cells (for review see [1^
4]).
The pathway of antigen presentation on the cell
surface of pathogens dwelling in the cytosol com-
prises proteins from di¡erent compartments. The
pathogens together with their intrinsic proteins are
degraded by the major cytosolic proteolysis machi-
nery, the 20S/26S proteasome (for review see [5^8]).
After cleavage, the peptides are translocated by the
transporter associated with antigen processing (TAP)
into the endoplasmic reticulum (ER) where assembly
of MHC class I molecules and peptides occurs. Sta-
ble ternary complexes consisting of heavy chain, L2-
microglobulin (L2-m) and bound peptide can leave
the ER for surface presentation to T cell receptor.
Every human has three to six di¡erent MHC class
I alleles for the presentation of antigens on the cell
surface. This low number of di¡erent MHC class I
molecules has to bind peptides of every non-self pro-
tein for presentation to CTL and protection of the
individuals against pathogens. As revealed by X-ray
crystallography, the antigenic peptides bind in a
groove formed by two K-helices on the rim and eight
L-strands on the bottom containing residues of the
K1 and K2 domains of the heavy chain of MHC class
I molecules [9^11]. The peptides are ¢xed via the free
amino- and carboxy-termini. In addition, anchor res-
idues at position two or three and at the carboxy-
terminal residue pointing into the groove are impor-
tant. In between these anchor residues, the side
chains point outside the groove which explains the
large pool of peptides that can be presented by one
MHC class I allele. Interestingly, the T-cell receptor
monitors this variable region [12,13]. The groove is
closed on both ends, therefore the size of the peptides
is determined to 8^10 residues in length.
The assembly of MHC class I molecules has been
well studied (for review see [14^16]). However, less is
known about how the peptides are generated and
transported into the ER [4,17]. The contribution of
the 20S proteasome for the generation of antigenic
peptides came from the observation that the two L-
type proteasomal subunits, LMP2 and LMP7 (low
molecular weight peptides), were identi¢ed within
the MHC locus [18^20]. The proteasome complex is
a multicatalytic macromolecular protease (700 kDa)
consisting of 28 subunits arranged in two outer rings
of K-type and two inner rings of L-type subunits (for
review see [5,7]). LMP2 and LMP7 are upregulated
by interferon-Q (INF-Q), which causes a structural
rearrangement of the 20S proteasome in which the
catalytically active subunits L2, L1 and L5 are re-
placed by MECL1 (multicatalytic endopeptidase
complex-like), LMP2 and LMP7, respectively, and
the so-called immunoproteasomes are formed. Con-
tradictory results exist about the functional di¡erence
and cleavage speci¢city of the immunoproteasome
compared to the proteasome consisting of constitu-
tively expressed L-type subunits. Due to the substi-
tution of the active subunits, the enzymatic activity
of the immunoproteasome cleaving after hydropho-
bic and basic substrates is increased whereas the pep-
tidyl-glutamyl activity is decreased in comparison to
the housekeeping proteasome [21^24]. This alteration
may ¢t with the preference of MHC class I molecules
for peptides with hydrophobic and basic carboxy-ter-
minal peptide residues. The peptides produced by the
proteasome have a size distribution of approximately
3^30 residues with a maximum of 6^11 residues
[21,25^27] which are also in part the size of the anti-
genic peptides bound in the groove of the binding
pocket of MHC class I molecules. In addition to
the proteasome, other proteases such as an IFN-Q-
inducible leucine aminopeptidase [28] or a giant cy-
tosolic protease system in the cytosol [29,30] may
play a role in epitope generation. Vinitsky and co-
workers showed that the presentation of antigenic
peptides of in£uenza viral proteins is not in£uenced
by blocking proteasomal activity [26]. In addition,
epitopes may also be produced by proteolytic trim-
ming in the ER after TAP-dependent transport [31].
The important role for peptide transport into the
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ER lumen became clear from studies of various cell
lines with a strongly reduced level of MHC class I
molecules on the cell surface [32,33]. Although the
expression levels of MHC class I heavy chain and
L2-m are normal and exogenously added peptides
or peptides introduced in the ER by a signal se-
quence were e⁄ciently presented, these defective
cell lines were unable to present intracellular antigens
on the cell surface. The defective phenotypes could
be restored by transfection of tap1 and/or tap2
[34,35]. The genes for human TAP1 and TAP2 are
located in the MHC II locus of chromosome 6 and
comprise 10 kb each. The genes are encoded by 11
exons. Eight exons have the same size and all exon/
intron boundaries are identical [36]. All four genes
are organized in an array lmp2, tap1, lmp7, tap2,
where only lmp2 is encoded on the (3) strand, sug-
gesting a duplication of an ancestral gene for a pro-
Fig. 1. Antigen processing and presentation via MHC class I molecules. Endogenous proteins including viral or tumor-speci¢c proteins
are degraded in the ubiquitin-proteasome pathway, and peptides are transported into the ER lumen by TAP. There, several molecules
have been implicated in the tightly regulated folding, assembly and loading of MHC class I molecules, including calnexin, calreticulin,
tapasin, ERp57, and possibly a peptide trimming activity. Stable MHC-peptide complexes can leave the ER via the Golgi compart-
ment to the cell surface for recognition by cytotoxic T lymphocytes.
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teasomal L type and TAP subunit followed by an
inversion of lmp2. Transcription of all four genes is
induced by IFN-Q, indicating a common regulation
and concerted function of these genes in antigen
processing.
By using isolated microsomes or semi-permeabi-
lized cells, ATP- and TAP-dependent peptide trans-
location into the ER was demonstrated [37^39]. In
addition, expression of TAP in insect cells and yeast
revealed that TAP is functional in the absence of
factors of the adaptive immune system [40,41]. In
addition to this major TAP-dependent translocation
mechanism, alternative, TAP-independent pathways
may exist for processing and loading of peptides
onto MHC class I molecules [42].
The TAP sequences of human, gorilla (Gorilla go-
rilla), mouse (Mus musculus/castaneus), rat (Rattus
norvegicus), hamster (Mesocricetus auratus), and sal-
mon (Salmo salar) show phylogenetic di¡erences as
expected. Human TAP1 possesses 98.8% homology
with gorilla TAP1, 69.2% with hamster TAP1 and
only 40% with salmon TAP1. The homology between
TAP1 and TAP2 in all species is approximately 35%
although they have a similar predicted membrane
topology. Thus, TAP1 and TAP2 seem to be derived
from an ancestral gene by gene duplication that hap-
pened before the evolution of the adaptive immune
system found in vertebrates.
The tap genes of all species examined are polymor-
phic, but only the rat alleles [43] as well as the most
recently discovered human TAP2iso splice variant
[44] possess di¡erent substrate speci¢city. The cim
(class I modi¢er) polymorphism in rat is based on
four tap2 alleles grouped into cima and cimb [43].
Cimb comprises the b and u alleles with a speci¢city
for hydrophobic, carboxy-terminal residues of the
processing peptide [45,46]. In contrast, the haplo-
types of cima (a and l) show a much broader specif-
icity and can transport peptides with basic or hydro-
phobic residues at the carboxy-terminus. The cima
and cimb alleles di¡er in 25 residues whereas only
two of them are located in the nucleotide binding
domain of TAP2. The remaining divergent residues
are in the amino-terminal half of the subunits. For
human or murine TAP approximately 10 polymor-
phic sites have been found for each subunit. How-
ever, these alleles do not show any di¡erence in sub-
strate speci¢city [47,48].
2. Structural organization of the TAP complex
TAP1 and TAP2 belong to the superfamily of
ATP-binding cassette (ABC) transporter that com-
prises a large number of polytopic integral mem-
brane proteins transporting a diverse set of molecules
across membranes in an ATP-dependent manner
[49,50]. ABC transporters are found in all three do-
mains of life representing in some organisms the larg-
est family of paralogous proteins. All ABC trans-
porters possess two conserved cytoplasmic ATP-
binding domains and two hydrophobic domains
comprising 5^10 transmembrane stretches, possibly
K-helices, lining up the putative translocation pore.
Although the structural organization of the ABC
transporters can be assumed to be very similar, the
hydrophobic transmembrane domains show only
very weak sequence homology. TAP1 or TAP2 are
so-called half-size transporters composed of a hydro-
phobic transmembrane domain (TMD) followed by a
highly conserved nucleotide binding domain (NBD).
There is 60% sequence identity within the NBDs and
only 30% between the TMDs of TAP.
Human TAP1 and TAP2 have a length of 748
amino acids (81 kDa) and 686 amino acids (75
kDa), respectively. The molecular weight determined
experimentally by SDS-polyacrylamide gel electro-
phoresis is 71 kDa for TAP1 and 75 kDa for
TAP2. Both proteins are located in the ER and cis-
Golgi [51] retarded by a so far unknown cryptic ER
retention signal. For human TAP2, an allele that is
17 amino acids longer (703 aa) has been identi¢ed
resulting from a polymorphic single base pair substi-
tution in the stop codon of the shorter TAP2 allele
[52]. Recently, a splice variant of hTAP2 with a
length of only 653 amino acids was detected [44].
As also found for other ABC transporters synthe-
sized at the ER, both TAP proteins lack an N-termi-
nal signal sequence for the import in the ER, sug-
gesting that an internal signal sequence may exist
promoting insertion in the ER membrane. TAP1
and TAP2 are found to be non-glycosylated although
human TAP1 has three consensus glycosylation sites,
two facing the cytosol and one placed in a short ER
loop which are too short for e¡ective glycosylation
by the oligosaccharide transferase [40]. A very minor
subpopulation of hTAP was found to be N-glycosyl-
ated [53] which may re£ect misfolded protein.
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By immuno-coprecipitation it was shown that
TAP1 and TAP2 assemble in the ER membrane to
form a heteromeric complex [54,55]. Coexpression of
TAP1 and TAP2 in TAP-de¢cient cell lines demon-
strated that both subunits are essential for antigen
processing [34,35,56]. Furthermore, no additional
factors of the immune system are required for TAP
function [40,41]. Gel ¢ltration analysis together with
more recent crosslinking experiments suggested that
TAP1 and TAP2 form a functional heterodimer
within the ER membrane with a stoichiometry of
1:1 [40,57,58].
As mentioned, the homology between the hydro-
phobic domains of ABC transporters is not very high
and so there is a variability in the number of trans-
membrane domains. Six transmembrane helices are
predicted for hemolysin transporter HlyB [59,60].
The subunits MalG and MalF of the maltose trans-
porter are supposed to contain six and eight trans-
membrane helices, respectively [61,62]. Some eukary-
otic ABC transporters show six transmembrane
helices of each hydrophobic domain with the amino-
and carboxy-terminus in the cytosol. Such a 2U6
transmembrane helix model could also be con¢rmed
for MDR1 [63,64]. As predicted from hydrophobicity
analysis, the membrane topology of human TAP1
and TAP2 is supposed to be di¡erent (Fig. 2) [65].
Sequence alignments with other ABC transporters
exclude the ¢rst 175 residues for hTAP1 and 140
residues for hTAP2. This part of TAP (N-domain)
displays no sequence homology with any protein. In
addition, the N-domain is very hydrophobic com-
prising four and three predicted transmembrane heli-
ces for TAP1 and TAP2, respectively. Although no
function of this amino-terminal hydrophobic region
is known so far, it can be speculated that it is essen-
tial for ER membrane targeting and correct assembly
of the complex. The rest of the transmembrane do-
main shows weak, but signi¢cant sequence homology
to MDR1 and other ABC transporters of the P-gly-
coprotein/TAP subfamily. The sequence similarity is
increased from TM1 to TM6. Based on the hydro-
phobicity analysis and sequence alignments with
MDR1 for which the membrane topology has been
extensively studied, a 2U6 transmembrane helix
model of TAP can be derived extended by an addi-
tional four and three transmembrane helices pre-
dicted for the N-domain [65]. Interestingly, the
TAP complex is highly asymmetric and only a very
small portion (6 10%) is in the ER lumen, whereas
large cytosolic loops and both NBDs are in the cy-
tosol.
In a ¢rst experimental approach, 10 transmem-
brane helices were reported for hTAP1 expressed in
Escherichia coli [66]. The topology was studied using
carboxy-terminal truncations of hTAP1 fused to L-
lactamase as reporter. This approach has been quite
successful in addressing the topology of several mem-
brane proteins of prokaryotes. However, care must
be taken if multisubunit ABC transporters from
highly specialized eukaryotic intracellular compart-
ments are studied. The topology model of hTAP1
found in this study contradicts the orientation of
the loop between TM5 and TM6 that has been iden-
ti¢ed by peptide photocrosslinking experiments to be
involved in peptide binding from the cytosol [67,68].
Di¡erences in membrane topology were also re-
ported for P-glycoprotein expressed in E. coli [64]
in comparison to the expression in eukaryotic cells
[69]. Notably, TAP1 expressed in E. coli is not func-
tional as large carboxy-terminal regions and the en-
tire TAP2 protein are missing, both are likely to be
essential for correct membrane insertion. It has been
further shown that even the insertion of an epitope, a
glycosylation targeting sequence or a protease cleav-
age site into transmembrane loops of ABC transport-
ers resulted in a loss of protein function and possibly
incorrect folding into the membrane. Thus, alterna-
tive methods have to be applied to address the top-
ology of the TAP complex. Following the elegant
approach reported for lactose permease [70] and
MDR1 [69,71], it will be interesting to construct cys-
teine-less mutants of TAP1 and TAP2 that are func-
tional. Subsequently, single cysteines can be intro-
duced in predicted loops and their accessibility can
be probed by thiol-speci¢c reagents. Mutation of all
19 cysteines of TAP is very time-consuming, but
these cysteine mutations are supposed to be mini-
mally invasive to the structure and function of TAP.
In TAP, the hydrophobic transmembrane domains
are linked to the nucleotide binding domains which
harbor the highly conserved ATP-binding cassette
consisting of the Walker A and B motifs (A/B) for
ATP binding and hydrolysis [72]. All ABC transport-
ers have a so-called C-loop (C) that comprises six to
eight conserved amino acids which are located sev-
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eral residues upstream of the Walker B sequence.
The ‘EAA’-like motif (E) found in the last cytosolic
loop of the membrane spanning domain of bacterial
ABC transporters [73] is less signi¢cant for TAP.
There is genetic evidence that this ‘EAA’ sequence
interacts via the C-loop with the nucleotide binding
domain and couples ATP-hydrolysis to the trans-
membrane spanning domain [74,75].
Peptides are photocrosslinked to TAP1 and TAP2
suggesting that both subunits contribute to peptide
binding [76,77]. In more recent studies, the peptide
binding site was mapped to regions of human TAP1
and TAP2. The crosslinked subunits were digested by
trypsin and/or bromocyan and crosslinked fragments
were immunoprecipitated with antibodies against
epitopes of putative loops in TMD [67,68]. The pro-
teolytic analysis of the crosslinked TAP subunits re-
vealed a similar binding region for TAP1 and TAP2.
The binding region comprises the cytosolic loop be-
tween putative TM4 and TM5 and a carboxy-termi-
nal stretch of approximately 15 amino acids follow-
ing TM6. Due to the topological model (Fig. 2), all
these binding regions are exposed to the cytosol. Re-
garding the transmembrane helices, TM4 to TM6
seem to be involved in peptide binding. For TAP2,
the ER-exposed loop between predicted TM1 and
Fig. 2. Membrane topology of the human TAP complex. The membrane topology was predicted by sequence alignment with human
MDR1 and using TopPredII (M.-G. Claros, Paris, France, based on the algorithm of Gunnar von Heijne). For the hydrophobicity
plot the following parameters were used (Kyte-Doolittle ; full window: 21; core window: 11). From the hydrophobicity plot four and
three transmembrane helices can be predicted for the hydrophobic N-terminal domain (N) of TAP1 and TAP2, respectively. The com-
munication between the NBD and TMD leads to tight coupling of peptide binding and ATP hydrolysis probably via contact of the
C-loop (C) and the ‘EAA’-like region (E). The Walker A (A) and B (B) regions ¢x the ATP at the nucleotide binding pocket.
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TM2 is also implicated in peptide binding [67]. The
identi¢ed photocrosslinked regions also comprise the
polymorphic residues 374 and 380 of rat TAP2 which
alter the substrate speci¢city in the rat TAP2a and
TAP2u alleles [78,79]. In future, a more detailed anal-
ysis of the substrate binding site may also become
possible using single cysteine mutants as described
above.
To obtain information about which subunit of the
TAP complex is involved in substrate speci¢city, Ar-
mandola and coworkers coexpressed TAP subunits
from di¡erent species and tested their substrate spe-
ci¢city using peptides with di¡erent carboxy-terminal
residues [80]. By using chimeric rTAP2a or rTAP2u
and hTAP2, residues located between residues 1 and
361 of hTAP2 were identi¢ed to a¡ect the speci¢city
for peptides with various carboxy-terminal residues.
Moreover, two pairs of residues (217/218) and (374/
380) of rat TAP and a single point mutation
(A374D) of human TAP a¡ect the substrate speci¢c-
ity [78,80]. Taking these data together, transport spe-
ci¢city with regard to the carboxy-terminal residue of
the peptide substrate is mainly a¡ected by TAP2, but
TAP1 can also contribute. The in£uence of TAP2 on
peptide binding seems to be more complex because
TAP2iso resembling a truncated splice variant of
hTAP2 showed an altered peptide speci¢city [44].
Thus, in addition of regions described above, the
last 33^51 carboxy-terminal amino acids of TAP2
seem also to contribute to peptide speci¢city. How
this carboxy-terminal region of TAP2 a¡ects the
peptide selection remains an open and puzzling ques-
tion.
Similar to P-glycoprotein [81,82], the region of
TM5 and TM6 of both subunits seems to build the
substrate binding site (Fig. 2). Less is known about
the peptide translocation pathway, but it can be
speculated that TM5 and TM6 are also part of a
translocation channel. Most strikingly, the putative
pore seems to have an extended diameter because
peptides with very large side chains such as £uoro-
phores or octapeptides can be e⁄ciently bound and
transported by TAP [83^85]. Interestingly, peptides
labeled with gold clusters of 1.4 nm in diameter bind
speci¢cally to TAP (L. Neumann and R. Tampe¤,
unpublished results). Moreover, some peptides con-
taining hydrophobic side groups have higher a⁄nity
for TAP than the unlabelled peptide [83,84].
Fig. 3. Model of substrate binding and translocation by the TAP complex. Peptide (R) and ATP bind to TAP from the cytosol in an
uncoordinated event. Under physiological conditions, it can be assumed that the NBDs are already loaded with ATP/ADP. Peptide
binding to TAP induces a structural reorganization of the TAP-peptide complex triggering ATP hydrolysis in the NBD which subse-
quently leads to the transport of the peptide across the ER membrane and the release in the ER lumen. However, we cannot distin-
guish whether ATP hydrolysis at both NBDs is required for substrate translocation (parallel mode) or whether ATP hydrolysis at one
NBD drives the translocation leaving the second NBD for completion of the transport cycle (sequential mode).
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3. Multistep transport mechanism of TAP
Peptide transport by TAP is a multistep process
(Fig. 3). Peptide associates with TAP in an ATP-in-
dependent manner following a monophasic 1:1
Langmuir binding model (A+BHAB) [83,86]. In di-
rect peptide binding or competition assays as well as
photocrosslinking experiments, no indication for a
second binding site was found. However, it cannot
be entirely ruled out that a second binding site with
very similar a⁄nity or alternatively with very low
a⁄nity exists. By using peptides labeled with an en-
vironmentally sensitive £uorophore, the association
pathway to TAP could be kinetically dissected in
real time [84]. Peptide binding to TAP is composed
of a fast bimolecular association step followed by a
slow isomerization of the TAP-peptide complex. This
structural reorganization may trigger the ATP hy-
drolysis and substrate translocation across the mem-
brane. TAP selectivity is primarily determined by the
¢rst bimolecular association step. Further evidence
for a structural isomerization of the TAP complex
was deduced from chemical crosslinking experiments
in which the level of crosslinked TAP heterodimers
increased in the presence of peptide [57].
Peptide translocation strictly requires the hydroly-
sis of MgWATP [37^40]. Non-hydrolyzable ATP ana-
logs, such as ATPQS, AMP-PNP or AMP-PCP, do
not promote peptide transport. Peptide transport can
be energized by ATP, UTP, CTP and GTP [39,87].
The Michaelis-Menten constant KM (MgWATP) for
peptide transport is 0.1^1 mM [87]. Direct binding
of nucleotides was demonstrated by 8-azido-ATP
photocrosslinking experiments [53,88,89]. Interest-
ingly, ATP and ADP have similar a⁄nity for TAP,
explaining that peptide transport can be inhibited by
ADP and other nucleoside diphosphates competing
for ATP binding [87]. Both nucleotide binding do-
mains interact with ATP even if separately expressed
[88,89]. However, the NBDs of TAP1 and TAP2 are
unable to hydrolyze ATP, suggesting that ATP hy-
drolysis requires a certain arrangement of both
NBDs via the transmembrane domains mediated by
peptide binding. In addition, both NBDs are essen-
tial for TAP function because mutation of one NBD
(R659Q of hTAP1) leads to a loss of transport func-
tion [90].
By partial puri¢cation and reconstitution into pro-
teoliposomes, the ATPase activity of the TAP com-
plex could be analyzed for the ¢rst time (S. Gorbulev
and R. Tampe¤, manuscript in preparation). The
ATPase activity is substrate-speci¢c and can be
blocked by a viral TAP inhibitor (see Section 5).
Most strikingly, the ATPase activity is tightly
coupled to peptide binding, indicating that substrate
binding is a requisite step for subsequent ATP
hydrolysis. Thus, peptide binding may cause a struc-
tural rearrangement of the NBDs that could function
as a molecular switch to activate the ATPase of TAP
thereby preventing the waste of ATP without trans-
location of peptides.
Regarding the ¢nal ATP-dependent translocation
step, important questions remain open. Do the two
NBDs work in sequential or synchronous fashion
which implies the question whether one or two
ATP are needed for a complete transport cycle? Fur-
thermore, are both NBDs equal in function, or does
ATP hydrolysis at one NBD drive the peptide trans-
location whereas hydrolysis at the other is needed for
completion of the transport cycle and reconversion
of the initial substrate binding site exposed to the
cytosol? It will be interesting to see in the future
how closely TAP resembles transport models of
MDR or CFTR (for review see [91]).
4. The substrate binding motif of TAP ^ coevolution
of a⁄nity, speci¢city and diversity
In contrast to our limited understanding of the
structure of TAP including the spatial arrangement
of the substrate binding pocket, the substrate specif-
icity of TAP has been well studied. The ¢rst gener-
ation of results came from experiments based on
trapping transported peptides in the ER via glycosyl-
ation. Comparing the number of glycosylated pep-
tides di¡ering in amino acid composition or length,
information about sequence and length preferences
of the transported peptides was extracted (for review
see [4,92,93]). The most e⁄cient transport was ob-
served for peptides with a length of 8^12 amino acids
[94] whereas van Endert et al. [86] showed an opti-
mum of peptides with 8^16 amino acids for peptide
binding. However, peptides of six or 40 amino acids
in length are also transported with TAP but with
lower e⁄ciency as compared to peptides with 8^12
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amino acids. In conclusion, TAP preferentially trans-
ports peptides similar or slightly larger in length suit-
able for MHC class I binding. In an alternative
approach, TAP selectivity was studied by ATP-
independent peptide binding assays [83,86]. The spe-
ci¢city studied with both methods showed the same
a⁄nity pattern for di¡erent substrates, but with no-
table di¡erences in absolute values of the a⁄nity for
TAP [76,83,95]. The glycosylation method may lead
to an underestimation of di¡erences of transported
peptides because this assay includes several side re-
actions such as transport, glycosylation, degradation
and peptide export. Each step has its own kinetic
parameter and speci¢city. In contrast, peptide bind-
ing to TAP is a simple bimolecular reaction. Thus,
the binding assay seems to be more accurate in re-
solving subtle details of the binding motif than the
glycosylation assay.
To resolve the recognition principle and the sub-
strate binding motif of TAP, complex peptide libra-
ries were applied [96]. With this combinatorial meth-
od comparing the average a⁄nity of a randomized
peptide mixture with one residue in common with a
totally randomized peptide mixture, it was possible
to determine the in£uence on the a⁄nity to TAP of
each peptide residue independently of a given se-
quence context. Thus, the e¡ect of each amino acid
residue on stabilization of peptide binding to TAP
could be determined. The peptide with the highest
a⁄nity showed a 45-fold higher a⁄nity than a totally
randomized peptide mixture resembling the selectiv-
ity of TAP for certain peptides. In a similar ap-
proach using an octapeptide library, a murine
MHC class I allele showed a 200-fold higher a⁄nity
for a high a⁄nity peptide [97]. On the basis of this
coarse comparison, TAP seems to be less restrictive
than MHC class I molecules. Most interestingly, the
e¡ect of amino acids on the binding to TAP is crit-
ically dependent on the position in the nonapeptide.
As reported earlier, the strongest di¡erences in pep-
tide binding a⁄nity were observed at the carboxy-
terminus of the peptides, as seen for some rat and
mouse alleles [45,98]. Human TAP showed a prefer-
ence for peptides with hydrophobic or basic amino
acids (Phe, Leu, Arg or Tyr) at the carboxy-terminus
which are also preferred peptide anchors for MHC
class I binding (Fig. 4). It should be mentioned that
none of the disfavored residues Asp, Glu, Asn or Ser
at the carboxy-terminus are anchors for peptide
binding to MHC class I molecules. Thus it can be
speculated that the recognition principle of TAP and
MHC class I molecules coevolved to transport pref-
erentially peptides which later on are bound to MHC
class I molecules. Moreover, there are hints that the
proteasomal subunits LMP2 and LMP7 upregulated
by INF-Q upon immune stimulation increase the
tryptic and chymotryptic activity of the proteasome
while reducing the peptidyl-glutamyl-peptide hydro-
lyzing activity [99]. Thus more peptides available for
MHC class I binding are generated. The amino-ter-
minal residues of peptides binding to TAP and to
MHC class I molecules do not agree very well. Hu-
man TAP favors Arg at the second peptide position
although Arg is only a weak anchor residue for cer-
tain MHC class I alleles at this position. In contrast,
Pro at position 2, reducing the a⁄nity for TAP dras-
Fig. 4. Substrate recognition motif and substrate binding pocket
of human TAP. TAP selectivity is illustrated for positions of
the peptide. Favored (white) and disfavored residues (black) of
TAP are given at the individual positions as extracted using
combinatorial peptide libraries [96]. A model of the substrate
binding pocket is shown in the lower panel.
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tically, is the preferred amino acid for other alleles at
this position. A similar e¡ect for Pro at position 3
was found for murine TAP [100] suggesting that it is
an important principle. Supported by a series of in-
dications, it can be speculated that an amino-termi-
nal exopeptidase located in the ER lumen processes
the peptides transported by TAP for loading of some
epitopes. This model is supported by the fact that
TAP transports peptides that are longer than those
bound to MHC class I molecules. While MHC class
I alleles use positions 2 and 3 as anchors at the ami-
no-terminus, position 1 of the peptide substrate is
also important for TAP selectivity. Here, Lys, Asn
and Arg are favored, whereas Asp and Glu weaken
TAP binding.
To determine the contribution of the peptide back-
bone and steric constraints to the peptide binding to
TAP, substrates with di¡erent lengths were modi¢ed
by D-amino acids in each position and tested for
TAP binding. Only D-amino acids in positions 1^3
and the carboxy-terminal position showed a strong
decrease in a⁄nity. This result together with the ef-
fect of proline in position 2 supports the idea that the
peptides are ¢xed at positions 1, 2 and 3 via contacts
mostly to the peptide backbone. The carboxy-termi-
nus of the peptide functions as a second important
anchor selecting for peptides with hydrophobic and
basic amino acids. Most importantly, the peptides
are ¢xed at the free amino- and the carboxy-terminus
via hydrogen bonding [96]. In analogy to MHC class
I molecules, it seems likely that the amino- and car-
boxy-termini contribute largely to the free binding
enthalpy [101]. In conclusion, residues and modi¢ca-
tions of the peptide within the amino- and carboxy-
terminal anchor regions do not in£uence the binding
and transport by TAP, indicating that this part of
the peptide does not interact with TAP (Fig. 4, lower
panel). This binding motif explains that longer pep-
tides can bulge out of the substrate binding pocket
and that modi¢cations by very large amino acid side
chains are tolerated within this region. Most strik-
ingly, the T cell receptors make contacts mainly be-
tween residues 5^8 of MHC class I-associated pepti-
des [12,13]. Thus, the T cell recognition takes place in
an area where TAP shows the lowest speci¢city,
therefore enlarging the pool of peptides presented
on MHC class I molecules. Thus, the proteasome,
TAP and MHC class I molecules might have co-
evolved a similar substrate speci¢city to optimize
the antigen processing machinery.
Fig. 5. Pathway of assembly of MHC class I molecules and formation of the macromolecular TAP-tapasin-MHC complex critical for
loading of antigenic peptides onto MHC class I molecules. Peptide-loaded MHC molecules can dissociate from the TAP complex. Ki-
netically unstable MHC-peptide complexes (fast koff ) are trapped and recycled by association with tapasin and TAP. Only kinetically
stable MHC complexes (slow koff )leave the ER via the Golgi to the cell surface (‘quality control mechanism’).
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5. TAP as part of a macromolecular transport and
chaperone complex
In the assembly and loading of MHC class I mol-
ecules a growing number of auxiliary, chaperone-like
proteins has been identi¢ed (for review see [102,103]).
Some of them are in close association with TAP (Fig.
5). Calnexin and calreticulin bind to monoglyco-
sylated core glycans in the ER lumen and increase
the e⁄ciency of correct folding of glycoproteins
(see review [104]). When the binding of these chap-
erones is inhibited, for example by glucosidase inhib-
itors, the folding and subsequent surface expression
of MHC class I molecules is drastically decreased
[105,106]. Calnexin, a type I membrane protein,
binds to nascent MHC class I heavy chain before
assembly with L2-m and correct folding occur. The
thiol-dependent reductase ERp57 found in complex
with MHC class I heavy chain, calnexin and calreti-
culin also binds in a very early step of the maturation
probably supporting the correct formation of the
conserved disul¢de bridges [107^109]. Then calreticu-
lin, a soluble protein with high sequence homology
to calnexin, binds to MHC class I heavy chain per-
haps displacing calnexin and supporting the assembly
of heavy chain and L2-m. Furthermore, calreticulin
seems to retain empty MHC class I molecules in the
ER. Most strikingly, MHC class I molecules are
found in close association with the TAP complex
[110,111]. As reported by Powis, MHC class I mole-
cules interact with TAP1 and TAP2 [112]. Approx-
imately four MHC class I molecules seem to be
linked via four tapasins to one TAP complex [58].
Tapasin is a ER-resident type I glycoprotein consist-
ing of two immunoglobulin folds [58,113]. The rea-
son for this unexpected stoichiometry could be the
presence of di¡erent MHC class I alleles to increase
the e⁄ciency of antigen processing and presentation.
In addition to its critical role in mediating the TAP-
MHC association, tapasin also has an important
function in the assembly and peptide loading of
MHC class I molecules probably based on a chaper-
one e¡ect. As shown by Lehner and coworkers, trun-
cated tapasin missing the transmembrane region and
the cytosolic tail does not associate with the TAP
complex but still rescues MHC class I surface expres-
sion [114]. Finally, tapasin increases the level of TAP
[114]. It is not unlikely that more, at the moment
unknown proteins are involved in the assembly and
loading of MHC class I molecules. In addition to the
thiol-dependent reductase activity, ERp57 also has a
cysteine protease activity that may possibly process
the TAP-derived peptides for optimal binding to
MHC class I molecules [107].
6. Implication in human diseases
In the past few years, it has become evident that
TAP is involved in several human diseases. Herpes-
and adenoviruses are known to interfere with antigen
presentation by a downregulation of MHC class I
molecules on the cell surface of virus-infected cells
(for review see [115]). The immediate early gene
product ICP47 of herpes simplex virus type 1
(HSV-1) was identi¢ed to inhibit peptide loading
onto MHC class I molecules thereby evading detec-
tion by cytotoxic T lymphocytes [116]. ICP47 inhibits
peptide translocation into the ER [117,118] by block-
ing the peptide binding site of TAP with high a⁄nity
[119,120]. ICP47 is highly species-speci¢c because the
a⁄nity for mouse TAP is 100-fold reduced in com-
parison to human TAP [119,120]. For the e⁄cient
inhibition of peptide binding a 32 amino acid frag-
ment comprising amino acid 3^34 of ICP47 is su⁄-
cient as seen by binding studies with truncated ICP47
[121]. Which part of the 32mer associates with the
peptide binding site is not known so far. However, a
photocrosslinker positioned on the amino-terminus
of the ICP47 fragment labels both subunits to the
same extent whereas 125I-labeled Tyr21 polypeptide
crosslinks only TAP1, suggesting that ICP47 is asym-
metrically bound to TAP [122]. Upon binding to
membranes, ICP47 seems to undergo a conforma-
tional change from a loosely folded to an K-helical
structure because structural studies showed that the
32mer is loosely structured in aqueous solution.
However, by binding to membranes, the polypeptide
seems to adopt an K-helical structure [123]. The
structure of the active domain of ICP47 was ana-
lyzed by NMR. In detergent solution, the active do-
main of ICP47 consists of two K-helices at residues
3^13 and 23^32 connected by a £exible loop [124].
Human cytomegalovirus encodes at least four dif-
ferent proteins that inhibit the cell surface expression
of MHC class I molecules in di¡erent ways and at
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di¡erent stages after infection (for review see [125]).
In contrast to ICP47, the ER-resident transmem-
brane class I glycoprotein US6, expressed late post
infection, binds probably to the ER-luminal part of
TAP, thereby inhibiting peptide translocation [126^
128]. US6 does not a¡ect the association of tapasin,
calreticulin and MHC class I molecules to TAP [126].
Moreover, the action of US6 can be overcome by
TAP induction with INF-Q. In contrast to ICP47,
which competes with peptides for the binding site
on TAP, US6 inhibits neither peptide binding nor
ATP binding to TAP (Fig. 6). Thus, it seems that
US6 blocks the translocation step by interacting with
the luminal part of TAP and prohibiting a conforma-
tional change required for peptide translocation.
Only little is known about congenital human TAP
de¢ciency. Inherited TAP de¢ciency in a family
caused by a stop codon at position 253 of TAP2
resulting in non-functional TAP has been described
[129]. The homozygous TAP23/3 siblings in this
family show a 100-fold decreased expression of
MHC class I molecules on the cell surface. Cytotoxic
Fig. 6. Viral escape mechanism of herpes simplex virus protein ICP47 and human cytomegalovirus protein US6 blocking TAP func-
tion from di¡erent compartments and by di¡erent mechanisms. The symbols are explained in Fig. 1.
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T lymphocytes were present in a reduced amount.
Despite this TAP de¢ciency, these siblings do not
show increased susceptibility to viral infection. In
further studies with MHC class I molecules expressed
in lymphoblastoid cell lines and cytotoxic T cells
derived from these individuals it was observed that
the antigens seem to be translocated to the ER lumen
in a TAP-independent manner [130].
At present, the participation of TAP in autoim-
mune diseases is a matter of controversy. Whereas
some publications report that TAP is linked to auto-
immune diseases, others report the opposite. Thus,
further studies will be necessary to elucidate the link-
age of TAP to autoimmune diseases.
In tumor cell lines and tumor tissues, a loss of
antigen presentation by MHC class I molecules is
often observed and the downregulation of MHC
class I surface expression can have various reasons
(for review see [131,132]). In some malignant tumors,
the de¢cient presentation of endogenous antigens on
the cell surface is caused by a drastically reduced
level of mRNA of TAP1, TAP2, LMP1 and LMP2
that could be restored by IFN-Q stimulation. In these
renal cell carcinomas, the transcription of TAP and
LMP seems to be downregulated by an unknown
mechanism [133]. Another interesting example of a
tumor escape mechanism was found in small lung
cancer where a TAP1 (R659Q) mutant was identi¢ed
[90]. Expression of MHC class I molecules on the cell
surface could be restored by expression of wild-type
TAP1 or adding exogenous peptides. R659 is local-
ized between the C-loop and the Walker B motif,
indicating that this mutation a¡ects ATP binding
or hydrolysis. The suppression of MHC class I mol-
ecules at the cell surface is a tumor escape mecha-
nism from immune recognition for tumor cells. How-
ever, it should kept in mind that these mechanisms
are more complex as cells lacking MHC class I mol-
ecules on the cell surface might become targets for
natural killer cells.
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